GuruFocus data shows that Christopher Anzalone, CEO of Arrowhead Pharmaceuticals Inc. ( ARWR), sold 146388 shares on February 22, 2012.
Insiders selling shares can cause investors concern. This could indicate that insiders have become bearish about the shares of their company's stock. Investors should pay close attention to insiders' ability to determine the company's value. We will take a closer look at the insider sale to determine if Arrowhead Pharmaceuticals Inc is worthy of some skeptical investors.
Christopher Anzalone trades
Christopher Anzalone sold 271388 shares over the last year.
Christopher Anzalone may have been selling the stock of their company over a more long-term. Contrary to what was expected, this could be a good sign for stock. Insiders selling frequently could indicate that their company has a large number of stock options for executives. Executives will sell some shares to raise cash. It is possible, however, that insiders became more bearish about the stock. Insider selling should not be taken lightly by investors.
Trends from the inside
One insider selling doesn't necessarily mean other insiders have a bearish view of the stock. Is the stock being sold by other insiders? Or have top company executives and owners bought more recently?
Arrowhead Pharmaceuticals Inc's insider transactions history shows that there were 1 insider buys over the last year. During the same period, 18 insider sales were made.
Christopher Anzalone has not been the only insider to sell shares in recent months. Other company insiders have also started selling more than buying, which can be problematic for investors. We should remember that insiders can sell shares for various reasons. A high level of insider sales could indicate a negative sign or neutral, depending upon the motivation behind it.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
